<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Telomerase reverse transcriptase (TERT) is a good candidate for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy because it is overexpressed in 85% of <z:hpo ids='HP_0000001'>all</z:hpo> human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and implicated in maintenance of the transformed phenotype </plain></SENT>
<SENT sid="1" pm="."><plain>TERT-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> is modest </plain></SENT>
<SENT sid="2" pm="."><plain>Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, in transgenic <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> mouse prostate mice, which develop <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, significantly prolonging mouse survival </plain></SENT>
<SENT sid="4" pm="."><plain>We also demonstrated that human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, including Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes </plain></SENT>
<SENT sid="5" pm="."><plain>Effective therapy with T cells against telomerase, different from active vaccination, however, led to <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> marked by a consistent, although transient, B-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy </plain></SENT>
</text></document>